Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $73.82 USD
Change Today -0.09 / -0.12%
Volume 1.8M
STJ On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

minimize changes in workflow prior to and immediately after an MRI scan. The company has initiated an Investigational Device Exemption (IDE) trial in the U.S. to further study the safety of the Accent MRI system to gain the U.S. approval. The company received FDA approval and European CE Mark approval of its Accent RF pacemaker and Anthem RF CRT-P. The Accent and Anthem product families feature RF telemetry that enables secure, wireless communication between the implanted device and the programmer used by the clinician, allowing for more efficient and convenient care and device management. The company’s pacing leads include the Optisense Optim, Tendril ST Optim, Tendril STS Optim lead families and the IsoFlex Optim, passive-fixation lead families, all available worldwide. All of these lead families feature steroid elution (to suppress the body's inflammatory response to a foreign object, such as a pacing lead), as well as the company’s Optim insulation. The company’s Optisense leads offer an electrode spacing technology that has been clinically proven to reduce far-field over-sensing and inappropriate mode switching. The company’s cardiac rhythm management devices interact with an external device referred to as a programmer. A programmer has two general functions. The company received FDA approval for the first software module of its Merlin Patient Care System, a universal programmer for the company’s ICDs and pacemakers. The company offers a new Pacing Systems Analyzer (PSA) that integrates into the Merlin programmer to allow for testing of the leads during device implant. In addition to the programmer, physicians could monitor implanted devices and patient status using the Merlin.net Patient Care Network. This system allows daily device and patient monitoring and scheduled remote follow-ups to occur in the patient's home rather than in the physician's office. The Merlin@home line of RF transmitters (FDA approval and European CE Mark approval) uses standard analog or DSL telephone lines, cellular networks or Wi-Fi to send device and therapy data stored in devices to an Internet site for retrieval and review by the patient's physician. With the Merlin.net Patient Care Network, physicians could manage their volume of ICD and pacemaker patients by conducting remote follow-up sessions and using alerts of clinically significant events. Additionally, patient flexibility is provided by the reduction in various office visits required and the ability to have a physician interrogate device data when symptoms warrant. The new version of this system received European CE Mark approval in 2013. This version would offer support for the company’s next generation Ellipse and Assura family of ICDs and CRT-Ds. AF Products The company’s AF products provide a complete system of access, diagnostic, visualization and ablation products that assist physicians in diagnosing and treating various irregular heart rhythms. Its ablation technologies are primarily designed to be used in the EP lab to guide and facilitate the percutaneous delivery of catheters to areas of the heart where arrhythmias occur. The company is committed to developing device-based ablation therapies for irregular heart rhythms that offer the potential for a cure. The company’s access products enable clinicians to facilitate the percutaneous delivery of diagnostic and ablation catheters to areas of the heart where arrhythmias occur. Its products include its Epicardial (EPI) Ablation System (FDA approval) with Agilis EPI to facilitate catheter delivery epicardially (outside the chambers of the heart) and the company’s Swartz and Swartz Braided Transseptal fixed-curve introducers to guide catheters to precise locations in the right and left atria. The company’s ultrasound product line consists of the ViewMate Z Intracardiac Ultrasound System and ViewFlex family of catheters. The company offers the ViewFlex Xtra 4-way Intracardiac Echocardiography catheter in the U.S. that features 4-way steering capabilities, and the company received European CE Mark approval in 2012. For diagnosing arrhythmias percutaneously, the company offers a portfolio of fixed-cur

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $73.82 USD -0.09

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.34 USD +0.09
CR Bard Inc $196.65 USD +3.55
Olympus Corp ¥4,750 JPY +5.00
Smith & Nephew PLC 1,189 GBp +22.00
Zimmer Biomet Holdings Inc $104.07 USD -0.78
View Industry Companies
 

Industry Analysis

STJ

Industry Average

Valuation STJ Industry Range
Price/Earnings 20.6x
Price/Sales 3.8x
Price/Book 5.5x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.